Data For New Alzheimer’s Disease Treatment For Agitation To Be Presented at Upcoming ANA Meeting

Data For New Alzheimer’s Disease Treatment For Agitation To Be Presented at Upcoming ANA Meeting
agitation drug for Alzheimer'sAvanir Pharmaceuticals, Inc. will present their most-recent results from two clinical trials currently underway for treating conditions associated with Alzheimer's disease (AD). The data is set to be presented at the American Neurological Association's (ANA) Annual Meeting in Baltimore, Maryland, from October 12-14, 2014. The phase II clinical trial evaluated AVP-923 safety, tolerability, and efficacy for the treatment of agitation in Alzheimer's patients. Agitati
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *